Healthcare - Q2FY21 Result Preview - ICICI Securities

The I-direct healthcare universe is expected to post YoY growth of 1.5% to Rs. 35944 crore on the back of currency driven growth in US formulations even as domestic growth is crawling back to normal. While domestic growth is still expected to continue to be impacted due to weak demand (acute segment) and lower MR footfalls, US formulations are expected to grow due to ramp-up in specialty products and new launches supported by currency tailwinds.

Net profit to de-grow ~8%

Net profit is expected to decline 8.3% YoY to Rs. 4244 crore mainly due to lower other income along with higher depreciation.

For details, click on the link below: https://www.icicidirect.com/mailimages/IDirect_Healthcare_Q2FY21.pdf

Source : Equity Bulls

Keywords